The deadly statistics of heart failure

Aldo P. Maggioni, MD, FESC

ANMCO Research Center

Firenze, Italy

Presenter Disclosures

Dr. Maggioni:

 Serving in Committees of studies on Heart Failure sponsored by: Bayer, Cardiorentis, Novartis Pharma AG

Agenda


- Hospitalized HF patients
- Chronic HF patients
- Conclusions and perspectives

Agenda

- Hospitalized HF patients

 The point of view of cardiologists
- Chronic HF patients
- Conclusions and perspectives

ESC HF Guidelines 2012: Algorithm for Management of Acute Pulmonary Edema/Congestion




Please consult published guidelines for additional treatment information.

IV = intravenous

SBP = systolic blood pressure

Adapted from McMurray JJ, et al. Eur J Heart Fail. 2012; 14(8): 803-869.


IN-HF Outcome: 1-year All-Cause Mortality



Tavazzi L, et al. Circ Heart Fail. 2013; 6:473-81.

ESC Heart Failure Long-Term Registry: Follow-up outcomes

Kaplan-Meier Curves for all-cause mortality




From May 2011 to April 2013, 21 countries, **12,440** patients, **40.5%** with **acute HF** (hospitalized patients) and **59.5%** with **chronic HF** (outpatients)

EORP: HF Long Term Registry, HFA Congress, Seville 2015


Agenda

- Hospitalized HF patients
 - -The point of view of cardiologists
 - -The Real World Evidence
- Chronic HF patients
- Conclusions and perspectives


Incidence of HF admissions in an Italian community setting in 2010



Age groups of the total population (A) and of patients admitted for HF (B)



Where are patients managed when admitted to hospital?




In-Hospital and 1 year all-cause mortality

In-hospital all-cause mortality: 9.8%


• 1- year all-cause mortality: **28.7%**

Patients with 12-month hospital re-admissions: 4,936/8,239 = 59.9%

Total number of readmissions = 7,840



NHS costs per year for 1 patient admitted for HF = € 10,697






- Hospitalized HF patients
- Chronic HF patients


 Patients' outcomes from 1995 to 2014

 Conclusions and perspectives


IN-HF: Patients disposition




1-year all-cause mortality by years of enrollment Overall population (n. 18,474 patients)




HF reduced EF (<45%) (n. 11,050 patients)




I-year all-cause mortality by years of enrollment <u>HF preserved EF (≥45%) (n. 3,215 patients)</u>



1A Recommended treatments by years of enrollment







- Hospitalized HF patients
- Chronic HF patients
- Conclusions and perspectives



- Due to the relevant advances in patients' treatment, outcomes in patients with chronic HF and reduced EF seem to be improved in the last decades
- Patients hospitalized for HF have generally a more severe clinical profile than those with chronic HF and a still unacceptably high rate of events
- Real world data confirm the clinical relevance of HF and the related burden on public health



- Further efforts should be focused on:
 - Widespread application of recommended treatments in patients with chronic HFrEF
 - New treatments (and trial methodology) for HHF and HFpEF patients
- Research projects should involve not only cardiology centers but also intensive care and internal medicine centers
- Due to multiplicity of causes of readmission, to concretely reduce the burden of HF, a multidisciplinary approach is needed